CHARACTERIZATION OF BRUCELLOSIS

布鲁氏菌病的特征

• 批准号: 8172720
• 负责人: Jean L. Patterson
• 金额: $ 17.27万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172720
• 关键词: Affect; Animal Model; Animals; Attenuated; Attenuated Live Virus Vaccine; Bacteria; Brucella; Brucella melitensis; Brucellosis; California; Categories; Cavia; Chronic; Computer Retrieval of Information on Scientific Projects Database; Disadvantaged; Disease Progression; Funding; Genetic; Goals; Grant; Granulomatous; Human; Immune; Immune response; Immunologic Markers; Inbred Strain; Infection; Institution; Macaca mulatta; Modeling; Mus; National Institute of Allergy and Infectious Disease; Organism; Pathogenicity; Pathologic; Physiology; Reagent; Research; Research Personnel; Resources; Source; Texas; United States National Institutes of Health; Vaccines; Virulent; nonhuman primate; pathogen; pre-clinical research; transmission process; vaccine development; weapons

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Brucellosis is a chronic granulomatous infection caused by several subtypes of the intracellular bacteria Brucella. There are less than 100 cases/year of natural brucellosis in USA, which occur predominantly in California and Texas; however, due to the possibility of airborne transmission of this pathogen, Brucella is considered a potential biologic weapon (NIAID category B agent). A human vaccine has not been developed for brucellosis, and some of the successful live-attenuated vaccines (LAV) used in animals still retain pathogenicity for humans. A major difficulty affecting the development of a vaccine against human brucellosis is the absence of well-established immune correlates of protection. Pathogenicity varies among Brucella species in all mammalian species evaluated. The mouse and guinea pig model of human vaccine development have the disadvantage of using inbred strains and consequent limited generalization of the results, and low availability of reagents for a thorough characterization of the immune response to the vaccines, respectively. Nonhuman primates (NHP) are the preferred animal models for pre-clinical research because they approximate humans in physiology and genetics more closely than any other animal. NHP are susceptible to infection with virulent or attenuated strains of Brucella organisms, and recent studies have shown that rhesus macaques infected with B. melitensis 16 M develop pathologic changes similar to the ones observed in human brucellosis. The immediate goal of this project is to define the rhesus macaque model for brucellosis and to identify potential immune markers of disease progression and protection.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 布鲁氏病是由细胞内细菌的几种亚型引起的慢性肉芽肿感染。 在美国，少于100例天然布鲁氏菌病，主要发生在加利福尼亚和德克萨斯州。但是，由于可能会传播这种病原体，因此布鲁氏菌被认为是潜在的生物武器（NIAID B类代理）。 人类疫苗尚未开发用于布鲁氏菌病，并且在动物中使用的一些成功的活疫苗（LAV）仍然保留了人类的致病性。 影响疫苗开发针对人性化的疫苗的主要困难是缺乏公认的保护性。 在评估的所有哺乳动物物种中，布鲁氏菌种的致病性各不相同。人类疫苗发育的小鼠和豚鼠模型的缺点是使用近交菌株，因此结果有限的概括，并且试剂的可用性较低，以彻底表征对疫苗的免疫反应的彻底表征。 非人类灵长类动物（NHP）是临床前研究的首选动物模型，因为它们比任何其他动物都更接近生理和遗传学的人类。 NHP易于感染毒性或减毒的布鲁氏菌生物，最近的研究表明，猕猴感染了16 m的恒河猴，形成了类似于人性乳纤维病中观察到的病理变化。 该项目的直接目的是定义布鲁氏菌病的恒河猴模型，并确定疾病进展和保护的潜在免疫标志物。